Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coral LaboratoriesBOM:524506 72 Net Margin % is 19.73% as of Mar. 2026, which is 40% above its 10-year median of 14.05. GuruFocus rates BOM:524506 with a GF Score™ of 72/100 and a GF Value™ of ₹483.47 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Coral Laboratories ranks better than 85.82% on this metric.
Coral Laboratories (BOM:524506) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Coral Laboratories Net Margin % Related Terms
Coral Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Coral Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Coral Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coral Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Coral Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Coral Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coral Laboratories (BOM:524506) has a Net Margin % of 19.73% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Coral Laboratories and its competitors. This is 40% above median its historical median of 14.05. Over the past decade, Coral Laboratories' Net Margin % has ranged from 8.27 to 21.00. According to the industry distribution chart, Coral Laboratories ranks #136 out of 959 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Coral Laboratories' Net Margin % too high?
Coral Laboratories' current Net Margin % of 19.73% is 40% above median its 10-year median of 14.05. Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 21.00. The Drug Manufacturers industry median Net Margin % is 5.32. Coral Laboratories' value of 19.73% is 270.9% above this industry median. Based on the distribution chart, Coral Laboratories ranks #136 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Coral Laboratories has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coral Laboratories' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Coral Laboratories ranks #136 out of 959 companies for Net Margin %. This places Coral Laboratories in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.32. Coral Laboratories' value of 19.73% is 270.9% above this benchmark. Historically, Coral Laboratories' own Net Margin % has ranged from 8.27 to 21.00 over the past decade. While the company's 10-year median is 14.05 vs. the industry median of 5.32, Coral Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coral Laboratories's current Net Margin % of 19.73% is 270.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Coral Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coral Laboratories's current Net Margin % is 19.73%, which is 40% above median its own 10-year median of 14.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coral Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Coral Laboratories (BOM:524506) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹483.47, compared to a current price of ₹577.90 — trading 19.5% above its estimated fair value. The current Net Margin % is 19.73%, which is 40% above median its 10-year median of 14.05 and 270.9% above the Drug Manufacturers industry median of 5.32. Coral Laboratories' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Coral Laboratories (BOM:524506), the current Net Margin % is 19.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coral Laboratories (BOM:524506) Overvalued in 2026?
Based on GuruFocus' analysis, Coral Laboratories stock appears to be overvalued.
The current stock price of ₹577.90 is trading 19.5% above its estimated GF Value™ of ₹483.47.
GuruFocus considers Coral Laboratories to be Modestly Overvalued.
Key valuation signals for BOM:524506:
Net Margin %: 19.73% (40% above median its 10-year median of 14.05)
GF Value™: ₹483.47 vs. price of ₹577.90 (19.5% above fair value)
Industry Position: 270.9% above the Drug Manufacturers median (#136 of 959)
No single metric tells the full story. See the BOM:524506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coral Laboratories Ltd is engaged in the pharmaceutical business. The company is involved in the formulation of medicines. The company's dosage form includes tablets, capsules, liquid orals, b-lactam, dry syrup, meter dose inhalers, injectables, drops, sprays, special kits, and others. Its geographical segments include Ethiopia, India, and the Rest of the world.
72GF Score
Get the complete analysis for BOM:524506
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524506 has been successfully added to your 
